BioSpace News Archive

Mylan N.V. announced its financial results for the year ended December 31, 2017 and Fourth Quarter 2017 and provided 2018 guidance.

C3J Therapeutics and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired function, announced an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.

Therap adds its 100th and 101st courses to its catalog of courses available in its Training Academy catalog.

The Mission LISA Foundation is pleased to announce its new Advisory Board, a group of expert stakeholders engaged in combatting the national opioid crisis through research, pain and addiction treatment, industry, and advocacy.

Ontotext is pleased to announce its partnership with Drugbank, which will empower commercial and academic Pharma and Healthcare researchers further in their efforts to discover and repurpose drugs for treating various illnesses.

Mylan N.V. and Revance Therapeutics, Inc. announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX® (onabotulinumtoxinA).

Glaukos Corporation announced financial results for the fourth quarter and full year ended December 31, 2017. Key highlights include:

Xanthic Biopharma Inc. announced that it has granted, effective today, an aggregate of 2,308,000 stock options to certain directors, officers, and consultants of the Xanthic in accordance with the Company’s current stock option plan.

Universal Health Services, Inc. announced that its reported net income attributable to UHS was $219.6 million, or $2.31 per diluted share, during the fourth quarter of 2017 as compared to $174.2 million, or $1.78 per diluted share, during the comparable quarter of 2016.

Concert Pharmaceuticals, Inc. announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet need.